"Most Favored Nation" pricing is one of the most consequential — and least understood — elements of the 2026 pharmaceutical tariff. If the MFN mechanism works as designed, it could fundamentally reshape how Americans pay for prescription drugs. Here is a complete explanation of what MFN pricing is, how it works under the current tariff, and what it actually means for patients.
What Is Most Favored Nation (MFN) Pricing?
In trade policy, the term "most favored nation" (MFN) means that a country treats a trading partner at least as favorably as its most favored trading partner. Applied to pharmaceutical pricing, MFN pricing means: a drug manufacturer must offer the US the same (or better) price as the lowest price it charges any other country.
If Novo Nordisk sells Ozempic in Germany for $80/month and in the US for $900/month, MFN pricing would require Novo Nordisk to offer Americans Ozempic at $80/month — Germany's price — because Germany is paying less than any other country.
MFN Pricing Under the 2026 Tariff
The Section 232 pharmaceutical proclamation created a specific MFN deal structure:
What companies agreed to:
1. Offer Americans pricing at or below their lowest price in any comparable developed country
2. Invest in domestic US pharmaceutical manufacturing capacity
3. Report pricing data to HHS to verify compliance
What they received in exchange:
- 0% tariff rate on all their covered drugs
- Earlier effective date (July 31, 2026) vs the 100% default date of September 29, 2026
The 13 companies that signed: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, EMD Serono, Genentech, Gilead Sciences, Merck, Novartis, Novo Nordisk, and Sanofi.
Is MFN Pricing New?
No — MFN drug pricing has been attempted before. The Trump administration issued an executive order on MFN pricing for Medicare Part B drugs in 2020, which was challenged in court and never implemented. The Biden administration implemented a different mechanism — direct Medicare drug price negotiation under the Inflation Reduction Act.
The 2026 MFN deal mechanism differs from previous attempts: it is a voluntary bilateral agreement (not a regulatory mandate), tied to tariff exemptions, and applies to the commercial market broadly — not just Medicare.
Will MFN Pricing Actually Lower Drug Costs?
This is the critical question — and the honest answer is: it depends on enforcement and implementation details that are not yet fully public.
Potential mechanisms for price reduction:
- Companies are obligated to offer MFN prices; HHS can theoretically verify and enforce
- Market competition: if MFN-deal companies lower prices, non-deal companies face pressure to follow
- Transparency: MFN pricing creates public benchmarks that insurers and PBMs can reference
Reasons for skepticism:
- US drug prices are set through complex net pricing systems involving rebates and discounts — list price reductions alone may not translate to patient-level savings
- "Comparable countries" definition matters enormously — if the comparator set excludes the cheapest markets, MFN doesn't achieve maximum savings
- Enforcement mechanisms are not well-specified in the public proclamation text
- Companies have incentives to raise prices in other countries to close the gap, rather than lower US prices
Historical note: Pharmaceutical companies are sophisticated at navigating pricing regulations. Whether this MFN mechanism achieves meaningful patient-level cost reductions or becomes a paper exercise in compliance will become clear in 2026–2028 as the deals operate.
Medicaid Drug Pricing: A Different MFN System
Separately from the tariff MFN deals, Medicaid already has a form of MFN pricing built in: the Medicaid Best Price rule. Under this rule, manufacturers must pay Medicaid a rebate that ensures Medicaid pays at most the lowest price the manufacturer charges any commercial customer (with exceptions).
This existing Medicaid best-price mechanism is one reason Medicaid drug costs are lower than commercial market costs for brand name drugs. It also creates a separate dynamic: if a company significantly lowers its commercial price under an MFN deal, its Medicaid rebate obligations could change.
Patented Drugs and MFN
MFN deals under the tariff apply specifically to patented brand-name drugs from the 13 Annex III companies. Patented drugs — those with active US patent protection listed in the FDA Orange Book — are the specific target of the 100% default tariff and the MFN deal mechanism.
Once a drug's patents expire and generics enter the market, the economics change entirely. Generics are fully exempt from the tariff, and the competitive dynamics of the generic market drive prices down without MFN mechanisms.
Use the MFN deal tracker for the current status of all 13 companies and check your specific medication's tariff classification with the drug search tool.